Last edition
News about "CuraTeQ Biologics"
CuraTeQ Biologics Announces Positive Phase 3 Results for BP11, Biosimilar to Xolair
CuraTeQ Biologics reports positive Phase 3 results for BP11, a biosimilar to Xolair, meeting primary endpoints in Chronic Spontaneous Urticaria (CSU) studies across Europe and India.
CuraTeQ Biologics | 07/04/2026 | By News Bureau
Aurobindo's Subsidiary CuraTeQ Biologics Completes Phase 3 Clinical Study for Denosumab Biosimilar
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has successfully completed a pivotal clinical study of its denosumab biosimilar, evaluated against Amgen’s Prolia in 446 women with postmenopausal osteoporosis.
CuraTeQ Biologics | 19/09/2025 | By Dineshwori | 342
CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.
CuraTeQ Biologics | 26/08/2025 | By Dineshwori | 255
CuraTeQ Biologics Secures UK MHRA Approval for Bevqolva
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.
CuraTeQ Biologics | 23/12/2024 | By Aishwarya | 630
Aurobindo Pharma Ltd's subsidiary to withdraw application for EU Marketing Authorization of two biosimilars
CuraTeQ Biologics | 26/06/2023 | By Sudeep Soparkar | 1004
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy